NetworkNewsBreaks – PreveCeutical Medical Inc. (
Post# of 77
(Total Views: 227)
Posted On: 09/21/2018 6:22:06 PM
NetworkNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Strategically Employs R and D Strategy to Achieve Increased Productivity
Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) aims to give its investors more bang for their buck when it comes to research and development (“R&D”), as it has been proven that smaller companies achieve higher R&D productivity. A recent article discussing the company reads: “PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) has taken this advice to heart. The health sciences company has three distinct research programs underway. Top of the line is a non-opioid pain treatment based on cannabinoids to be administered through a proprietary nose-to-brain, soluble gel (Sol-gel) drug delivery system. The research team is also out to identify peptides and proteins derived from the venom of the Caribbean blue scorpion that may have therapeutic use. The company is also working on a smart RNA dual gene therapy for the treatment of type 2 diabetes and obesity.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) aims to give its investors more bang for their buck when it comes to research and development (“R&D”), as it has been proven that smaller companies achieve higher R&D productivity. A recent article discussing the company reads: “PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) has taken this advice to heart. The health sciences company has three distinct research programs underway. Top of the line is a non-opioid pain treatment based on cannabinoids to be administered through a proprietary nose-to-brain, soluble gel (Sol-gel) drug delivery system. The research team is also out to identify peptides and proteins derived from the venom of the Caribbean blue scorpion that may have therapeutic use. The company is also working on a smart RNA dual gene therapy for the treatment of type 2 diabetes and obesity.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)PreveCeutical Medical Inc. (PRVCF) Stock Research Links
Scroll down for more posts ▼